<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069573</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE-36787714.0.0000.5152</org_study_id>
    <nct_id>NCT03069573</nct_id>
  </id_info>
  <brief_title>Phenotypic Characterization and Biomarkers Investigation for Eosinophilic Esophagitis in Pediatric Patients</brief_title>
  <official_title>Phenotypic Characterization of Pediatric Patients With Esophageal Eosinophilia and Biomarkers Investigation for the Diagnosis of Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Uberlandia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Uberlandia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out some potential biomarkers for the Eosinophilic&#xD;
      Esophagitis (EoE) in pediatric patients through the prospective clinical characterization and&#xD;
      assessment of samples collected during the diagnostic process&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study collects clinical information from pediatric patients between 0-18 years old who&#xD;
      have been undergoing upper gastrointestinal endoscopy due to general complaints. The&#xD;
      demographic, clinical symptoms, endoscopy, pH monitoring, and histology data are assessed&#xD;
      during the diagnostic process. In the baseline endoscopy procedure samples (blood, saliva,&#xD;
      esophageal tissue, and esophageal mucus) are taken. After diagnostic process of EoE and&#xD;
      Gastroesophageal reflux disease (GERD) supported by International Guidelines the patients are&#xD;
      divided into three groups - EoE, GERD, and Control.&#xD;
&#xD;
      The techniques are used for patients characterization and assessment:&#xD;
&#xD;
        1. Symptoms score: General symptom score and/or Pediatric Eosinophilic Esophagitis Symptom&#xD;
           Score (PEESS v2.0) - translated and adapted version for Brazilian Portuguese&#xD;
&#xD;
        2. Endoscopic Score: Eosinophilic Esophagitis (EoE) Endoscopic Reference Score (EREFS)&#xD;
&#xD;
        3. Peak eosinophil count (PEC) and histological features description&#xD;
&#xD;
        4. Proteomic analyses&#xD;
&#xD;
        5. Microbiome analyses&#xD;
&#xD;
        6. Immunohistochemistry analyses&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Biomarkers for the diagnose of Pediatric Eosinophil Esophagitis</measure>
    <time_frame>2016 August - 2017 March and 2018 November-December</time_frame>
    <description>Identify diagnostic biomarker, able to distinguish EoE patients from GERD patients and other nonspecific gastrointestinal complains</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic features of EoE</measure>
    <time_frame>2017 January-March and 2018 November-December</time_frame>
    <description>Evaluation of the EREFS 'ability (endoscopic reference score) to identify EoE patients and the inflammatory or fibrosis phenotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of active EoE</measure>
    <time_frame>2017 January-March and 2018 November-December</time_frame>
    <description>Evaluation of the symptom score's ability to identify EoE patients in active disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological features of EoE</measure>
    <time_frame>2017 January-March and 2018 November-December</time_frame>
    <description>Evaluation of the histologic score's ability to identify EoE patients and the inflammatory or fibrosis phenotype</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Eosinophilic Esophagitis - EoE</arm_group_label>
    <description>Diagnosis of pediatric EoE under current guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastroesophageal reflux disease - GERD</arm_group_label>
    <description>Diagnosis of pediatric GERD under current guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Exclusion diagnosis of EoE or GERD, with non specific gastrointestinal general complaints.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, saliva, esophageal tissue, esophageal mucus&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive pediatric patients undergoing esophagogastroduodenoscopy (due to general&#xD;
        complaints) at a Tertiary Public Health Care Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients who are undergoing upper gastrointestinal endoscopy for diagnostic&#xD;
             purpose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients who are undergoing upper gastrointestinal endoscopy for therapeutic&#xD;
             procedures&#xD;
&#xD;
          -  The presence of other eosinophilic diseases&#xD;
&#xD;
          -  Patients have been taken corticosteroids and/or gastric acid secretion inhibition&#xD;
             drugs for the last four weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz Ricardo Goulart, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Uberlandia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Palmer Barros, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Uberlandia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Uberlandia</name>
      <address>
        <city>Uberl√¢ndia</city>
        <state>Minas Gerais</state>
        <zip>38400-902</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SH, Spechler S, Spergel JM, Straumann A, Wershil BK, Rothenberg ME, Aceves SS. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2. doi: 10.1016/j.jaci.2011.02.040. Epub 2011 Apr 7. Review.</citation>
    <PMID>21477849</PMID>
  </reference>
  <reference>
    <citation>Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, Sondheimer J, Staiano A, Thomson M, Veereman-Wauters G, Wenzl TG, North American Society for Pediatric Gastroenterology Hepatology and Nutrition, European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):498-547. doi: 10.1097/MPG.0b013e3181b7f563.</citation>
    <PMID>19745761</PMID>
  </reference>
  <reference>
    <citation>Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013 Apr;62(4):489-95. doi: 10.1136/gutjnl-2011-301817. Epub 2012 May 22.</citation>
    <PMID>22619364</PMID>
  </reference>
  <reference>
    <citation>Singla MB, Chehade M, Brizuela D, Maydonovitch CL, Chen YJ, Riffle ME, Achem SR, Moawad FJ. Early Comparison of Inflammatory vs. Fibrostenotic Phenotype in Eosinophilic Esophagitis in a Multicenter Longitudinal Study. Clin Transl Gastroenterol. 2015 Dec 17;6:e132. doi: 10.1038/ctg.2015.62.</citation>
    <PMID>26680264</PMID>
  </reference>
  <reference>
    <citation>Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology. 2010 Aug;139(2):418-29. doi: 10.1053/j.gastro.2010.05.001. Epub 2010 May 7.</citation>
    <PMID>20457157</PMID>
  </reference>
  <reference>
    <citation>Aceves SS, Newbury RO, Dohil MA, Bastian JF, Dohil R. A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. Ann Allergy Asthma Immunol. 2009 Nov;103(5):401-6. doi: 10.1016/S1081-1206(10)60359-6.</citation>
    <PMID>19927538</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 19, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Uberlandia</investigator_affiliation>
    <investigator_full_name>Cristina Palmer Barros</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Eosinophilic Esophagitis</keyword>
  <keyword>Gastroesophageal Reflux</keyword>
  <keyword>Diagnose</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

